Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals Llc (ACXP)
:ACXP
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.28Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -29.79%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call presents a generally positive outlook for Acurx Pharmaceuticals, highlighted by significant clinical advancements and regulatory support for its lead candidate, ibezapolstat. Despite financial challenges and the need for additional funding, the company has made meaningful progress in reducing its losses and securing a new patent. Management remains confident in addressing potential NASDAQ listing concerns.Company Guidance
In the recent call, Acurx Pharmaceuticals discussed several key metrics and updates relevant to their fiscal year 2024 performance and future plans. The company reported a net loss of $2.8 million for the fourth quarter of 2024, a decrease from the $5.1 million loss in the same period of 2023. For the full year, the net loss was $14.1 million, a slight improvement from the $14.6 million loss in 2023. Cash reserves at the end of 2024 were $3.7 million, down from $7.5 million at the end of 2023. Research and development expenses decreased to $0.8 million for the last quarter of 2024, primarily due to reduced consulting costs, while general and administrative expenses also fell to $2 million for the same period. The company is poised to advance its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials, with regulatory alignment from both the FDA and EMA. Acurx secured $2.5 million from a direct offering in January 2025 and an additional $1.1 million in a March 2025 offering, underscoring its ongoing efforts to fund its clinical programs.Advancement to Phase 3 Trials
Acurx is finalizing preparation to advance ibezapolstat into international Phase 3 clinical trials for treating C. difficile infection, with the potential for regulatory approval in both the US and EU.
Positive Phase 2b Clinical Results
Ibezapolstat demonstrated a 100% clinical cure rate in the Phase 2 program, with no infection recurrence in patients followed for three months post-treatment.
Regulatory Support from FDA and EMA
Received positive regulatory guidance from both the FDA and EMA, aligning on the Phase 3 program's clinical, non-clinical, and manufacturing aspects.
New Patent in Japan
Granted a new patent for DNA polymerase IIIC inhibitors, supporting ongoing development of ACX-375C, with potential applications against MRSA, VRE, and Anthrax.
Financial Improvements
Net loss decreased to $2.8 million in Q4 2024 from $5.1 million in Q4 2023, with significant reductions in research and development and administrative expenses.
---
ACXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ACXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $0.47 | $0.40 | -14.89% |
| Nov 13, 2024 | $1.85 | $1.82 | -1.62% |
| Aug 09, 2024 | $1.90 | $1.88 | -1.05% |
| May 15, 2024 | $2.09 | $2.25 | +7.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Acurx Pharmaceuticals Llc (ACXP) report earnings?
Acurx Pharmaceuticals Llc (ACXP) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Acurx Pharmaceuticals Llc (ACXP) earnings time?
Acurx Pharmaceuticals Llc (ACXP) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACXP EPS forecast?
ACXP EPS forecast for the fiscal quarter 2025 (Q1) is -0.13.
---